Overview

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
A Drug-Drug Interaction study to assess the effects of EDP-235 on the Pharmacokinetics and Safety of midazolam, caffeine and rosuvastatin.
Phase:
Phase 1
Details
Lead Sponsor:
Enanta Pharmaceuticals, Inc
Treatments:
Caffeine
Midazolam
Rosuvastatin Calcium